Linda Montgomery • January 10, 2024
Trial Participation- There is still time to join!

HCM Clinical Trial Opportunities 

We’ve been urging you to learn a few important points about your disease because HCM has various presentations and important metrics.


  • Are you obstructed or non-obstructed?
  • What is your Ejection Fraction – (EF)?
  • What is your NYHA functional class?
  • If you have a genetic mutation, if so, what is it?

Knowing the answers to these questions gives a healthcare provider a snapshot of your disease and also facilitates eligibility for clinical trials.  


Current trials:

  • The first is the Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM). For more information, please complete this survey: https://www.surveymonkey.com/r/pulse3
  • Other myosin inhibitor trials regarding the Efficacy and Safety of Aficamten. For information about this and other trials, please complete the survey: https://www.surveymonkey.com/r/pulselet6
  • MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. For more information, please complete this survey: https://www.surveymonkey.com/r/peak10
  • For our younger HCM community members with the MYBPC3 gene, a study: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB ).

If you are interested in any of these trial opportunities, please send me an email with your contact information – my email is linda@4hcm.org


If you haven’t gone through the HCMA Intake process within the last two years, please schedule an Intake Call on the website https://4hcm.org/education-and-support/

This will give us the best understanding of your current health, HCM presentation, and potential eligibility in upcoming trials.

HCMA Blog

Cytokinetics Logo of a green
By Erica Friedman May 14, 2025
Positive clinical trial endpoints for MAPLE-HCM study announced by Cyctokonetics for aficamten in obstructive hypertrophic cardiomyopathy
A Caucasian hand with a pen rests on a clipboard that holds paper with writing.
By Gordon Fox May 14, 2025
In the third of a series about decision-making and risk in HCM, Gordon Fox explains where risk data comes from and how to understand it.
4 diverse people stand under the mathmateical formula 25% = 1 in 4.
By Gordon Fox May 13, 2025
In part three of this series on decision making in HCM, Gordon Fox discusses how medical professionals define risk within a patient population, and what the different kinds of risk mean for a patient.
More Posts